In gene therapy development, definitive GLP toxicology and biodistribution studies often receive the most attention. These studies are complex, costly, and frequently sit on the critical path to regulatory submission. However, the quality of those studies is often shaped by decisions made much earlier.

Before a sponsor commits to a pivotal GLP program, a well-designed dose range-finding study can provide critical information to support study design and risk reduction. It can help assess dose feasibility, biological response, route tolerability, tissue distribution, immune activation, and overall endpoint strategy. These data can then inform key elements of the definitive study, including dose selection, tissue collection plans, sampling schedules, recovery periods, humane endpoints, and specialized assessments such as qPCR/ddPCR biodistribution, vector shedding, immunogenicity testing, ophthalmic or neurologic evaluations, and expanded histopathology.

This is especially important for AAV and other in vivo gene therapy platforms, where dose selection is rarely based on tolerability alone. A sponsor may also need to understand whether the vector reaches the intended target tissue, whether off-target tissues are exposed, whether immune responses emerge, and whether the planned route of administration is practical and reproducible.

In this context, dose range-finding is not simply a preliminary toxicology study. It is a strategic planning tool that helps connect early development assumptions with the operational demands of GLP toxicology and biodistribution.

Why Early Dose Selection Matters

A definitive GLP toxicology study should not be used to guess the dose range. It should generate high-quality, interpretable, regulatory safety data. If dose selection is poorly informed, the study may be difficult to interpret even when it is well executed.

If the high dose is too low, the study may not adequately characterize toxicity, demonstrate relevant exposure margins, or support the proposed clinical dose. If the high dose is too aggressive, it may produce excessive toxicity, immune activation, severe clinical signs, or early termination, limiting interpretability and creating avoidable welfare concerns.

For gene therapy products, the challenge is broader than selecting a tolerated dose. Dose levels may need to account for vector genome dose, target tissue exposure, off-target biodistribution, transgene expression, route-specific tolerability, systemic immune activation, and manufacturing concentration limits.

Connecting Dose Range Finding to Biodistribution Strategy

Biodistribution is central to many gene therapy toxicology programs and is often best understood as a PK/TK-like assessment for gene therapy products. It helps sponsors understand the kinetic pattern of the AAV test article and its complex components (vector DNA, transgene RNA) under multiple dose levels in the DRF, where the vector travels, which tissues are exposed, and how distribution patterns relate to safety findings.

Dose range finding can strengthen the biodistribution strategy by helping determine:

• which dose levels are biologically meaningful; • whether higher doses increase target tissue exposure or mainly increase systemic distribution; • which target and off-target tissues should be prioritized; • whether additional timepoints are needed; • whether immune or organ-specific findings require expanded tissue evaluation.

This upstream planning matters because biodistribution studies are highly execution-dependent. Tissue collection, necropsy workflow, sample handling, chain of custody, contamination control, cold-chain logistics, and assay readiness all influence the quality of the final dataset. Operational excellence ensures the biodistribution study is executed properly. Dose range-finding helps ensure the right questions are being asked before that operational machinery is put in motion.

The High Dose Is Not Simply the Highest Possible Vector Dose

In gene therapy, the high dose should be scientifically justified, not merely set at the highest technically feasible or manufacturable level.

Depending on the program, the high dose may be guided by expected pharmacologic activity, target tissue transduction, biodistribution profile, immune activation, systemic exposure, route-specific tolerability, maximum feasible concentration or volume, manufacturing constraints, and regulatory expectations.

If increasing the vector dose does not meaningfully improve target tissue exposure but increases systemic distribution or immune activation, the higher dose may not improve the value of the study. Similarly, if the route of administration becomes technically difficult or locally injurious at higher concentrations or volumes, those effects may obscure the true biological safety profile.

De-Risking the GLP Program Before It Begins

Early DRF data can help determine whether:

• the proposed dose range is appropriate; • the intended clinical route is feasible; • the selected test system is biologically relevant; • target tissue exposure is sufficient; • off-target distribution requires additional monitoring; • immune activation is dose-related; • recovery groups or longer observation periods are needed; • specialized endpoints should be added; • tissue collection and bioanalytical plans are fit for purpose.

This creates a stronger bridge between scientific design and operational execution. The GLP study is then more likely to generate data that are interpretable, complete, and aligned with the sponsor’s regulatory strategy.

Supporting Welfare and Study Quality

Gene therapy studies can involve complex administration routes, longer observation periods, and extensive tissue collection. A smaller pilot study can help refine the definitive design before larger test system numbers are committed.

This supports the 3Rs by reducing the risk of excessive toxicity, improving monitoring plans, refining humane endpoints, and lowering the likelihood that a pivotal GLP study will need to be repeated because of poor dose selection or incomplete endpoint planning.

A Better Path to Operational Excellence

For gene therapy sponsors, the lesson is straightforward: de-risking does not begin at necropsy, or even at first dose in the GLP study. It begins earlier, when the program still has the flexibility to refine the dose range, route, endpoints, and biodistribution strategy.

Sometimes, the most important study is not the largest one. It is the pilot study that makes the pivotal study worth doing.

Attentive Science supports sponsors with decision-driven nonclinical study design, including dose range-finding studies, toxicology, pharmacokinetics, safety pharmacology, biodistribution-supportive workflows, and gene therapy-supportive programs designed to generate meaningful, development-enabling data. Contact Us to speak to leading experts and derisk your program in real time.